Agenus Inc (AGEN) - Total Liabilities
Based on the latest financial reports, Agenus Inc (AGEN) has total liabilities worth $414.44 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Agenus Inc to track the company's year-over-year net asset growth rate.
Agenus Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Agenus Inc's total liabilities have evolved over time, based on quarterly financial data. See Agenus Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Agenus Inc Competitors by Total Liabilities
The table below lists competitors of Agenus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Waton Financial Limited Ordinary Shares
NASDAQ:WTF
|
USA | $5.31 Million |
|
Den Networks Limited
NSE:DEN
|
India | Rs4.57 Billion |
|
TRUFIN PLC
F:29U
|
Germany | €14.17 Million |
|
NIIT Limited
NSE:NIITLTD
|
India | Rs1.78 Billion |
|
STLLR Gold Inc.
TO:STLR
|
Canada | CA$8.05 Million |
|
Zapata Computing Holdings Inc. Common Stock
NASDAQ:ZPTA
|
USA | $19.36 Million |
|
HIM International Music
TWO:8446
|
Taiwan | NT$685.28 Million |
|
Avita Medical Inc
AU:AVH
|
Australia | AU$69.39 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Agenus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AGEN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Agenus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Agenus Inc (1999–2025)
The table below shows the annual total liabilities of Agenus Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $504.66 Million | -5.26% |
| 2024-12-31 | $532.70 Million | +15.23% |
| 2023-12-31 | $462.30 Million | -1.32% |
| 2022-12-31 | $468.46 Million | +12.06% |
| 2021-12-31 | $418.05 Million | -1.87% |
| 2020-12-31 | $426.01 Million | +10.17% |
| 2019-12-31 | $386.67 Million | +24.35% |
| 2018-12-31 | $310.95 Million | +45.15% |
| 2017-12-31 | $214.22 Million | +9.23% |
| 2016-12-31 | $196.11 Million | +14.35% |
| 2015-12-31 | $171.50 Million | +232.95% |
| 2014-12-31 | $51.51 Million | +31.01% |
| 2013-12-31 | $39.32 Million | -15.80% |
| 2012-12-31 | $46.69 Million | +14.90% |
| 2011-12-31 | $40.64 Million | -10.91% |
| 2010-12-31 | $45.61 Million | -27.42% |
| 2009-12-31 | $62.85 Million | -22.28% |
| 2008-12-31 | $80.86 Million | -11.72% |
| 2007-12-31 | $91.60 Million | +1.39% |
| 2006-12-31 | $90.35 Million | +25.04% |
| 2005-12-31 | $72.25 Million | +171.47% |
| 2004-12-31 | $26.61 Million | -23.60% |
| 2003-12-31 | $34.83 Million | +208.11% |
| 2002-12-31 | $11.31 Million | -35.84% |
| 2001-12-31 | $17.62 Million | +56.46% |
| 2000-12-31 | $11.26 Million | +161.91% |
| 1999-12-31 | $4.30 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more